Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma CDMO offers integrated end-to-end solutions for development & commercialization of intermediates & APIs for small molecules.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    veranova-m-2025-06-30

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Brolucizumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 4Beovu

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Beovu

    Brolucizumab

    arrow
    Pharmex
    Not Confirmed

    Brand Name : Beovu

    Switzerland
    arrow
    Pharmex
    Not Confirmed

    Novartis

    Brolucizumab

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2020 Revenue in Millions : 190

    2019 Revenue in Millions : 35

    Growth (%) : 443

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Beovu

    Brolucizumab

    arrow
    Pharmex
    Not Confirmed

    Brand Name : Beovu

    Switzerland
    arrow
    Pharmex
    Not Confirmed

    Novartis

    Brolucizumab

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2021 Revenue in Millions : 186

    2020 Revenue in Millions : 190

    Growth (%) : -2

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Beovu

    Brolucizumab-dbll

    arrow
    Pharmex
    Not Confirmed

    Brand Name : Beovu

    Switzerland
    arrow
    Pharmex
    Not Confirmed

    Novartis

    Brolucizumab-dbll

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2022 Revenue in Millions : 203

    2021 Revenue in Millions : 186

    Growth (%) : 9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Beovu

    Brolucizumab

    arrow
    Pharmex
    Not Confirmed

    Brand Name : Beovu

    Switzerland
    arrow
    Pharmex
    Not Confirmed

    Novartis

    Brolucizumab

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2019 Revenue in Millions : 35

    2018 Revenue in Millions : 0

    Growth (%) : New launch

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF